Mei Ri Jing Ji Xin Wen·2025-09-08 22:21Group 1 - Hanbang Technology received a decision from the National Intellectual Property Administration declaring the patent rights of Cytiva's "separation medium slurry tank" invalid, reflecting the principle of equal treatment in China's intellectual property protection system [1] - Zhaoyan New Drug announced that its directors and executives plan to reduce their holdings in the company due to personal financial needs, which may raise short-term stock price concerns among investors [2] - Zhixiang Jintai obtained approval for clinical trials of its GR2303 injection, a monoclonal antibody targeting TL1A for treating inflammatory bowel disease, indicating significant clinical development value [3] Group 2 - Lude Medical's actual controller plans to reduce his holdings by 2.48 million shares, accounting for 1.4212% of the total share capital, reflecting urgent personal financial needs [4] - Buchang Pharmaceutical's subsidiary is set to invest in a new company, Shaanxi Buchang Medical Data Pharmaceutical Co., Ltd., aiming to integrate pharmaceutical resources with digital capabilities, aligning with the trend of digital transformation in the pharmaceutical industry [5]